Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 10/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16632537 | 0.98 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23875083 | 0.84 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14923484 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17564382 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14923699 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14923728 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14923533 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13617298 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL22383165 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25534687 | 0.82 | CA1 (0.48) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | claimed |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1318142-B1 | T-BUTOXYCARBONYLAMINOETHYLAMINE FOR THE SYNTHESIS OF PNA MONOMER UNITS, AMINO ACID DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESSES FOR PRODUCTIONS OF THEM | CREDIA JAPAN CO LTD (JP) | 2007-04-11 | — | — | EP | claimed |
| US-20050187402-A1 | T-butoxycarbonylaminoethylamine for the synthesis of PNA monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | CREDIA JAPAN CO., LTD. (JP) | 2005-08-25 | — | — | US | claimed |
| US-20040101839-A1 | Novel functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| US-20040039224-A1 | T-butoxycarbonylaminoethylamine for the synthesis of pna monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | CREDIA JAPAN CO., LTD. (JP) | 2004-02-26 | — | — | US | claimed |
| EP-1357112-A1 | NOVEL FUNCTIONAL PEPTIDE NUCLEIC ACID MONOMER AND PROCESS FOR PRODUCING THE SAME | Applied Biosystems Japan Ltd. (JP) | 2003-10-29 | — | — | EP | claimed |
| EP-1318142-A1 | T-BUTOXYCARBONYLAMINOETHYLAMINE FOR THE SYNTHESIS OF PNA MONOMER UNITS, AMINO ACID DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESSES FOR PRODUCTIONS OF THEM | Applied Biosystems Japan Ltd. (JP) | 2003-06-11 | — | — | EP | claimed |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240058371-A1 | MOLECULE FOR INDUCING SPONTANEOUS CALCIFICATION OF TUMOR CELLS AND USE THEREOF | ZHEJIANG UNIVERSITY (CN) | 2024-02-22 | — | — | US | disclosed |
| WO-2023144723-A1 | IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| WO-2023084396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-1997001579-A2 | SOMATOSTATIN PEPTIDES | NOVARTIS AG (CH) | 1997-01-16 | — | — | WO | disclosed |
| US-5587478-A | BONDING TO OLIGONUCLEOTIDES, DRUG DELIVERY, THERAPHY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-12-24 | — | — | US | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5470855-A | Anticoagulants | SANOFI (FR) | 1995-11-28 | — | — | US | disclosed |
| US-5204482-A | Ethylenediamine monoamide heteroaryl derivatives | HOFFMAN-LAROCHE INC. (US) | 1993-04-20 | — | — | US | disclosed |
| US-5011849-A | Monoamine oxidase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | CA1 670/4885CA2 1750/4885CA7 1193/4885 |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | DCK, DHPS, DHX15 | CA1 2711/4885CA2 3718/4885CA7 2220/4885 |
| US-20240058371-A1 | MOLECULE FOR INDUCING SPONTANEOUS CALCIFICATION OF TUMOR CELLS AND USE THEREOF | CASR, CALCOCO2, CACYBP | CA1 25/4885CA2 6/4885CA7 202/4885 |
| US-20040101839-A1 | Novel functional peptide nucleic acid monomer and process for producing the same | NSUN3, NSUN2, RNGTT | CA1 2420/4885CA2 1902/4885CA7 2214/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | CA1 3384/4885CA2 3833/4885CA7 3439/4885 |
| US-20050187402-A1 | T-butoxycarbonylaminoethylamine for the synthesis of PNA monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | BCAT1, BCAT2, RNGTT | CA1 1059/4885CA2 3002/4885CA7 2159/4885 |
| US-20040039224-A1 | T-butoxycarbonylaminoethylamine for the synthesis of pna monomer units, amino acid derivatives, intermediates thereof, and processes for productions of them | BCAT1, BCAT2, RNGTT | CA1 648/4885CA2 1906/4885CA7 1254/4885 |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | CA1 3208/4885CA2 2398/4885CA7 3271/4885 |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | PBRM1, STAMBP, TSPO | CA1 3216/4885CA2 3677/4885CA7 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.